Problem: Which statement best describes the FDA warning for aspiration added to product labeling of some antiobesity medications? Need Assignment Help? A. GLP-1 agonists may increase the risk of aspiration pneumonia with long-term therapy. B. Dual GLP-1 agonist/glucose-dependent insulinotropic polypeptide therapies are not associated with this increased risk. C. Patients undergoing major surgery should stop GLP-1 therapies at least 1 week to decrease their aspiration risk. D. The aspiration risk applies only to those patients on GLP-1/GIP agents receiving general anesthesia or deep sedation.